Sharechat Logo

AFT's Crystaderm antiseptic approved for sale in China

Tuesday 21st November 2023

Text too small?

AFT Pharmaceuticals (ASX: AFP, NZX: AFT ) today announces its first aid antiseptic cream Crystaderm has been approved for sale in China, the world’s second largest healthcare market.

The registration by China’s relevant government agency will allow the medicine to be sold in China. Currently AFT sells the medicine into China via its Cross Border E-Commerce (CBEC) site on Tmall China.

AFT Managing Director Dr Hartley Atkinson says: “We are delighted with the approval of this medicine and excited about the growth opportunities it opens for the company. This is consistent with our International expansion plans.

“Crystaderm is one of our most popular products in New Zealand and is a key focus on our Tmall site. We believe it has the potential for success in Chinese E-commerce sites and over the counter medicine outlets. We are still firming up plans for the distribution of this medicine in China, but we expect it to be launched in the market in the 2024 calendar year.”

Crystaderm is a preservative-free first aid cream used for the treatment and prevention of minor skin infections such as acne, cuts, scrapes, grazes, burns and school sores (impetigo). Unlike topical antibiotics it carries no known risk of bacterial resistance and consequently in New Zealand has been widely prescribed by doctors. Hydrogen peroxide, its active ingredient, is a potent agent against many types of bacteria. The medicine is designed to melt at skin temperature and to release the active ingredient to both moist and dry areas, and doesn’t stain skin, hands, or fabric.



Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Investors Media

Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232


About AFT Pharmaceuticals

AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Devon Funds Morning Note - 21 June 2024
Infratil announces opening of NZ$150 million Retail Offer
NZGIF backs Sunergise with $10m lending facility
FBU Enters Agreement to Divest 50pc of Fiji Construction
FBU - WA Plumbing Australia - Response to BGC Claims
June 14th Morning Report
ENS - Enprise appoints Aaron Ridgway as a Non-Executive Director
AIR - Departure of Chief Corporate Affairs Officer